Michael Stepanavage

1.9k total citations · 1 hit paper
16 papers, 1.3k citations indexed

About

Michael Stepanavage is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cancer Research. According to data from OpenAlex, Michael Stepanavage has authored 16 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Surgery, 4 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Cancer Research. Recurrent topics in Michael Stepanavage's work include Lipoproteins and Cardiovascular Health (10 papers), Cancer, Lipids, and Metabolism (4 papers) and Cholesterol and Lipid Metabolism (3 papers). Michael Stepanavage is often cited by papers focused on Lipoproteins and Cardiovascular Health (10 papers), Cancer, Lipids, and Metabolism (4 papers) and Cholesterol and Lipid Metabolism (3 papers). Michael Stepanavage collaborates with scholars based in United States, Australia and Norway. Michael Stepanavage's co-authors include Michael H. Davidson, Yale Mitchel, Philip J. Barter, Hayes M. Dansky, Antonio M. Gotto, Sukrut Shah, Eliot A. Brinton, Christopher P. Cannon, Patrice H. Gibbons and Jennifer Ng and has published in prestigious journals such as New England Journal of Medicine, Circulation and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Michael Stepanavage

16 papers receiving 1.3k citations

Hit Papers

Safety of Anacetrapib in Patients with or at High Risk fo... 2010 2026 2015 2020 2010 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
    2010 544 citations Christopher P. Cannon, Sukrut Shah et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Stepanavage United States 11 905 540 254 242 167 16 1.3k
Neil Hounslow United Kingdom 16 604 0.7× 305 0.6× 207 0.8× 149 0.6× 167 1.0× 35 858
Kathryn A. Krueger United States 17 568 0.6× 574 1.1× 199 0.8× 174 0.7× 86 0.5× 29 1.7k
Mike K. Palmer United Kingdom 17 745 0.8× 344 0.6× 169 0.7× 530 2.2× 230 1.4× 26 1.4k
Devaki Nair United Kingdom 23 708 0.8× 244 0.5× 161 0.6× 480 2.0× 74 0.4× 53 1.8k
S Marcovina United States 18 1.0k 1.1× 751 1.4× 383 1.5× 306 1.3× 56 0.3× 26 1.6k
Jemma C. Hopewell United Kingdom 22 766 0.8× 420 0.8× 262 1.0× 428 1.8× 112 0.7× 58 1.8k
Stephen Donahue United States 14 583 0.6× 166 0.3× 106 0.4× 118 0.5× 281 1.7× 31 1.1k
Jong-Soon Park United States 12 793 0.9× 632 1.2× 133 0.5× 375 1.5× 171 1.0× 27 1.7k
Rachid Massaad United States 18 447 0.5× 151 0.3× 163 0.6× 133 0.5× 215 1.3× 38 754
Mary Jane Geiger United States 20 748 0.8× 542 1.0× 237 0.9× 552 2.3× 246 1.5× 31 2.5k

Countries citing papers authored by Michael Stepanavage

Since Specialization
Citations

This map shows the geographic impact of Michael Stepanavage's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Stepanavage with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Stepanavage more than expected).

Fields of papers citing papers by Michael Stepanavage

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Stepanavage. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Stepanavage. The network helps show where Michael Stepanavage may publish in the future.

Co-authorship network of co-authors of Michael Stepanavage

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Stepanavage. A scholar is included among the top collaborators of Michael Stepanavage based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Stepanavage. Michael Stepanavage is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Davidson, Michael H., Philip J. Barter, Eliot A. Brinton, et al.. (2012). Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. Journal of Lipid Research. 54(2). 467–472. 37 indexed citations
2.
3.
Lakoski, Susan G., Gloria Lena Vega, Scott M. Grundy, et al.. (2011). Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin (Journal of Clinical Endocrinology and Metabolism (2010) 95, (800-809)). 96(5). 1 indexed citations
4.
Cannon, Christopher P., Sukrut Shah, Hayes M. Dansky, et al.. (2010). Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. New England Journal of Medicine. 363(25). 2406–2415. 544 indexed citations breakdown →
5.
Cannon, Christopher P., Hayes M. Dansky, Michael H. Davidson, et al.. (2009). Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib. American Heart Journal. 158(4). 513–519.e3. 65 indexed citations
6.
Lakoski, Susan G., Fang Xu, Gloria Lena Vega, et al.. (2009). Indices of Cholesterol Metabolism and Relative Responsiveness to Ezetimibe and Simvastatin. The Journal of Clinical Endocrinology & Metabolism. 95(2). 800–809. 60 indexed citations
7.
Davidson, Michael H., et al.. (2005). Striated Muscle Safety of Ezetimibe/Simvastatin (Vytorin). The American Journal of Cardiology. 97(2). 223–228. 38 indexed citations
8.
Pollack, Pia S., et al.. (2005). Pregnancy outcomes after maternal exposure to simvastatin and lovastatin. Birth Defects Research Part A Clinical and Molecular Teratology. 73(11). 888–896. 69 indexed citations
9.
Ose, Leiv, Tamás Szamosi, Claude Gagné, et al.. (2002). Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia. Circulation. 106(17). 2231–2237. 220 indexed citations
10.
Tfelt‐Hansen, Peer, et al.. (2002). The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double‐blind, placebo‐controlled, crossover study in normal subjects. British Journal of Clinical Pharmacology. 54(1). 38–44. 7 indexed citations
11.
Stepanavage, Michael, Aditi Shahane, Minzhi Liu, & Mei Wu. (2001). Some Statistical Methods to Differentiate a Treatment Effect for Small Shifts in the Tail of a Distribution. Drug Information Journal. 35(4). 1235–1246. 1 indexed citations
12.
Stein, Evan A., Michael H. Davidson, Adrian S. Dobs, et al.. (1998). Efficacy and safety of Simvastatin 80 mg/day in hypercholesterolemic patients. The American Journal of Cardiology. 82(3). 311–316. 56 indexed citations
13.
Sciberras, David, William J. Polvino, Barry J. Gertz, et al.. (1997). Initial human experience with MK-462 (rizatriptan): a novel 5=HTIDagonist. British Journal of Clinical Pharmacology. 43(1). 49–54. 28 indexed citations
14.
Zhang, Ji, Hui Quan, Jennifer Ng, & Michael Stepanavage. (1997). Some statistical methods for multiple endpoints in clinical trials. Controlled Clinical Trials. 18(3). 204–221. 137 indexed citations
15.
Sciberras, David, William J. Polvino, Barry J. Gertz, et al.. (1997). Initial human experience with MK‐462 (rizatriptan): a novel 5=HTID agonist. British Journal of Clinical Pharmacology. 43(1). 49–54. 43 indexed citations
16.
Bachmann, Kenneth, Timothy J. Sullivan, James H. Reese, et al.. (1995). Controlled Study of the Putative Interaction Between Famotidine and Theophylline in Patients with Chronic Obstructive Pulmonary Disease. The Journal of Clinical Pharmacology. 35(5). 529–535. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Neil Hounslow Breakdown of academic impact, for papers by Kathryn A. Krueger Breakdown of academic impact, for papers by Mike K. Palmer Breakdown of academic impact, for papers by Devaki Nair Breakdown of academic impact, for papers by S Marcovina Breakdown of academic impact, for papers by Jemma C. Hopewell Breakdown of academic impact, for papers by Stephen Donahue Breakdown of academic impact, for papers by Jong-Soon Park Breakdown of academic impact, for papers by Rachid Massaad Breakdown of academic impact, for papers by Mary Jane Geiger
Rankless by CCL
2026